ST. PAUL, Minn.--(BUSINESS WIRE)-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that AGA Medical, Inc. (acquired by St. Jude Medical in November 2010) has filed lawsuits against Occlutech GmbH and Occlutech U.K. (collectively Occlutech) for patent infringement. The suits, which involve a total of three patents and seek injunctive relief and monetary damages, were filed in Germany and the U.K. at the District Court of Duesseldorf and the High Court of Justice, Chancery Division, Patents Court, respectively.
The patent infringement lawsuits allege that products distributed by Occlutech, namely the companies’ atrial septal defect (ASD) and patent foramen ovale (PFO) closure/occlusion devices, infringe on key patents used for the St. Jude Medical Amplatzer® occlusion device platform. The platform, which is comprised of nitinol-based occlusion devices and accessories, offers minimally invasive transcatheter treatments for the safe and effective closure of structural defects found in a patient’s heart.
"St. Jude Medical has made significant investments in the structural heart space,” said Frank Callaghan, president of the St. Jude Medical Cardiovascular Division. “From clinical research to important product advancements, AGA Medical and now St. Jude Medical, has contributed considerably to the success of this marketplace. St. Jude Medical values the innovations we bring to the industry and will closely protect our intellectual property so we can continue to bring leading-edge products to the health care professionals we serve worldwide.”
AGA Medical has been engaged in litigation against Occlutech since 2006.
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended April 2, 2011. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
KEYWORDS: United Kingdom United States Europe North America Minnesota Germany
INDUSTRY KEYWORDS: Surgery Health Biotechnology Cardiology Medical Devices Medical Supplies